US equities |
SPCX $171.09 ▲+0.00% NVDA $238.90 ▲+0.00% MU $1,063.96 ▲+0.00% SNDK $1,704.16 ▲+0.00% AMD $631.75 ▲+0.00% SDEV $3.94 ▲+0.00% SKHY $195.02 ▲+0.00% TSLA $378.73 ▲+0.00%
FinancialContent

Articles published by Satellos Bioscience Inc.

< Previous 1 2 Next >
News headline image
Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSLE TSX:MSCL
News headline image
Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSLE TSX:MSCL
News headline image
Satellos to Participate in Upcoming Investor Conferences
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSLE TSX:MSCL
News headline image
Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSLE TSX:MSCL
News headline image
Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters’ Option to Purchase Additional Shares
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSLE TSX:MSCL
News headline image
Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States
From Satellos Bioscience Inc.
Via Business Wire
Tickers TSX:MSCL
News headline image
Satellos Announces Launch of Public Offering in Canada and the United States and Filing of Application to List on Nasdaq
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Announces Share Consolidation in Connection with Proposed Nasdaq Listing
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Receives Clearance by U.S. FDA and Global Regulators to Initiate Pediatric Phase 2 Study of SAT-3247 for Duchenne Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos to Participate in December Investor Conferences
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Announces Publication in Nature Communications Supporting its Novel Treatment Approach for Duchenne Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Reports Third Quarter 2025 Results and Announces Appointment of Mark Nawacki to Board of Directors
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos to Participate in November Investor Conferences
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Announces First Adult Patient Dosed in LT-001, an Open-Label, Long-Term Follow-Up Study of SAT-3247 in Duchenne Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Announces New Data Further Demonstrating Safety, Tolerability, and Functional Impact of SAT-3247 in First-in-Human Trial of Adults with Duchenne Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos to Present SAT-3247 Phase 1 Clinical Data in Late-Breaking Poster Session at the 2025 World Muscle Society Congress
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Announces IND Submission to the U.S. FDA and Global Regulatory Filings to Advance a Phase 2 Clinical Trial of SAT-3247 in Children with Duchenne Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos to Participate in Four September Institutional and Retail Investor Conferences
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Reports Second Quarter 2025 Results and Highlights Upcoming Clinical Milestones
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos to Present at Canaccord Genuity’s 45th Annual Growth Conference
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Bioscience Shareholders Elect Two New Board Members
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Bioscience Announces Results of Annual and Special Meeting of Shareholders
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Bioscience to Participate in PPMD’s Annual Conference in Las Vegas
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Announces Encouraging Functional Data from the 28-day Phase 1b Open-Label Trial of SAT-3247 in Adults with Duchenne Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Reports First Quarter 2025 Results and Highlights Recent Company Progress
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos to Present at the CureDuchenne FUTURES National Conference
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos to Present at Bloom Burton & Co. Healthcare Investor Conference
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
< Previous 1 2 Next >